AbbVie Inc (ABBV)vsInnovative Eyewear Inc. (LUCY)
ABBV
AbbVie Inc
$258.09
-1.81%
HEALTHCARE · Cap: $442.36B
LUCY
Innovative Eyewear Inc.
$0.94
-16.70%
HEALTHCARE · Cap: $5.89M
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 2159997% more annual revenue ($64.39B vs $2.98M). ABBV leads profitability with a 9.8% profit margin vs -272.5%. ABBV earns a higher WallStSmart Score of 73/100 (B).
ABBV
Strong Buy73
out of 100
Grade: B
LUCY
Hold38
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-74.9%
Fair Value
$151.49
Current Price
$258.08
$106.59 premium
Margin of Safety
+16.7%
Fair Value
$1.32
Current Price
$0.94
$0.38 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Growing faster than its price suggests
Every $100 of equity generates 62 in profit
Strong operational efficiency at 40.0%
Earnings expanding 290.4% YoY
Conservative balance sheet, low leverage
Reasonable price relative to book value
Revenue surging 70.2% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
Premium valuation, high expectations priced in
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -102.4% — below average capital efficiency
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, PEG Ratio, Return on Equity. Revenue growth of 10.2% demonstrates continued momentum. PEG of 0.41 suggests the stock is reasonably priced for its growth.
Bull Case : LUCY
The strongest argument for LUCY centers on Price/Book, Revenue Growth, Debt/Equity. Revenue growth of 70.2% demonstrates continued momentum.
Bear Case : ABBV
The primary concerns for ABBV are P/E Ratio, Altman Z-Score. A P/E of 70.5x leaves little room for execution misses.
Bear Case : LUCY
The primary concerns for LUCY are EPS Growth, Market Cap, Return on Equity.
Key Dynamics to Monitor
ABBV profiles as a value stock while LUCY is a hypergrowth play — different risk/reward profiles.
LUCY carries more volatility with a beta of 2.71 — expect wider price swings.
LUCY is growing revenue faster at 70.2% — sustainability is the question.
ABBV generates stronger free cash flow (3.2B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (73/100 vs 38/100) and 10.2% revenue growth. LUCY offers better value entry with a 16.7% margin of safety. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Innovative Eyewear Inc.
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Innovative Eyewear Inc. (LUCY) stands at the forefront of the smart eyewear sector, merging advanced technology with appealing aesthetics to meet the needs of modern, tech-savvy consumers. Its flagship product line, Lucyd, is designed to provide integrated audio features and seamless connectivity, offering a blend of convenience and style. Firmly focused on enhancing user experience and driving innovation, LUCY is well-positioned to leverage the growing demand for multifunctional eyewear, creating significant growth opportunities in a rapidly evolving market. As the trend towards smart, connected devices accelerates, LUCY’s strategic initiatives to promote its product offerings place it in a strong position for long-term competitiveness and success.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?